Advances in anti-VEGF/VEGFR targeting drugs for corneal neovascularization

Authors: Wang Qun,  Huang Yifei
DOI: 10.3760/cma.j.issn.2095-0160.2015.12.018
Published 2015-12-10
Cite as Chin J Exp Ophthalmol, 2015,33(12): 1138-1143.

Abstract                              [Download PDF] [Read Full Text]

Cornea is an important part of the refractive media.Healthy cornea is clear and avascular.Corneal avascularity is necessary for the preservation of optimal vision and is maintained by a balance between angiogenic and antiangiogenic factors.In a variety of pathologic conditions, the balance between angiogenic and antiangiogenic factors may be tipped towards angiogenic molecules, leading to corneal neovascularization (CNV). Recent research showed that vascular endothelial growth factor (VEGF) is an important factor responsible for CNV.Over the past several years, the safety and efficacy of several new agents targeting VEGF or VEGF receptor (VEGFR) have been verifies in many ocular neovascularization diseases such as age-related macular degeneration, diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity and CNV.These agents not only have revolutionized the therapy of ocular neovascularized disease but also have great potential for other blinding conditions such as CNV.These agents have great potential for the treatment of CNV.This article reviewed the most promising anti-VEGF/VEGFR therapies.

Key words:

Corneal neovascularization; Vascular endothelial growth factor; Vascular endothelial growth factor receptor; Targeting drug

Contributor Information

Wang Qun
Department of Ophthalmology, The General Hospital of Chinese People’s Armed Police, Medical School of PLA, Beijing 100853, China
Huang Yifei
(Read 8 times, 1 visits today)
Updated: February 27, 2023 — 7:07 am